Drawing for ASCENDIS PHARMA

USPTO serial 79225147

ASCENDIS PHARMA

Reviewed by CopyMark Law Group

Reg. 6630735Status 700Renewal
Filing date
Status date
Registration date
Feb 1, 2022
Examiner
SHOOR, AMIT KUMAR
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ASCENDIS PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $975

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Eric T. Fingerhut

Eric T. Fingerhut Dykema Gossett PLLC1301 K Street, N.W.Suite 1100 WestWashington, DC 20005

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicidesACTIVE—
042Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technologyACTIVE—
045Licensing of industrial property; legal servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 15, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 12, 2026ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Mar 10, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 1, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 13, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 13, 2022FIMPFINAL DISPOSITION PROCESSED—
May 1, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 1, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 24, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 23, 2021GPNXNOTIFICATION PROCESSED BY IB—
Nov 16, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 16, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 28, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 27, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 27, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 27, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 13, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 12, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 12, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 12, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 9, 2021GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 9, 2021GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 9, 2021CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 10, 2021DOCKASSIGNED TO EXAMINER—
Mar 16, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 15, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 15, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 15, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 15, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 15, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 15, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 15, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 15, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 15, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 15, 2021EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Mar 15, 2021EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Mar 15, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 15, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 14, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 18, 2020RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jun 3, 2020ALIEASSIGNED TO LIE—
Nov 21, 2019RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jul 5, 2019OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jun 19, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jun 19, 2019OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
May 9, 2019RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Oct 19, 2018GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 19, 2018GNSLLETTER OF SUSPENSION E-MAILED—
Oct 19, 2018CNSLSUSPENSION LETTER WRITTEN—
Oct 1, 2018DMCCDATA MODIFICATION COMPLETED—
Sep 28, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 27, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 27, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 14, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 17, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 17, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 16, 2018ALIEASSIGNED TO LIE—
Jul 26, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 24, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 24, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 2, 2018RFNTREFUSAL PROCESSED BY IB—
Feb 9, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 9, 2018RFRRREFUSAL PROCESSED BY MPU—
Feb 7, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 6, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 2, 2018RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Jan 30, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 29, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 23, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 19, 2018DOCKASSIGNED TO EXAMINER—
Jan 19, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 18, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance